Lilly today began filing a rolling submission of study data to the FDA for its #Alzheimers drug #donanemab, reports @Loftus. ADDF believes a combination therapy approach with drugs targeting a variety of pathways will ultimately be key to treatment on.wsj.com/3nxEuTX @WSJ
1
4
3
0
1